AI in Endoscopy Market Size, Share & Trends Analysis by AI Technology, Component, Application, Indication, Deployment Model, End User, and Geography - Global Opportunity Analysis and Industry Forecast

The global AI in Endoscopy Market is estimated to be valued at USD 2.31 billion in 2026 and is projected to reach USD 19.7 billion by 2036, expanding at a CAGR of 22.4% during the forecast period. The report provides a comprehensive evaluation of artificial intelligence-enabled software platforms, AI-integrated endoscopic systems, and associated services that leverage machine learning, deep learning, computer vision, and natural language processing to assist clinicians during and after endoscopic procedures, examining market trends, technological advancements, competitive developments, and future growth opportunities across the value chain.

AI in endoscopy is deployed primarily across two functional paradigms: computer-aided detection (CADe), which operates in real time to identify and highlight suspected lesions within live video streams, and computer-aided diagnosis and characterization (CADx), which provides real-time optical assessment of lesion histology and malignancy risk to support resect-or-leave decisions. Beyond detection and characterization, the market spans automated bowel preparation scoring, withdrawal time monitoring, natural language processing-based documentation, and AI-enabled disease activity scoring for conditions such as inflammatory bowel disease. As clinical evidence for AI-assisted colonoscopy matures from early feasibility studies into large randomized controlled trials, AI is transitioning from an early-adopter technology into an emerging clinical quality standard across endoscopy units globally.

This report delivers an in-depth assessment of the market by analyzing technological innovations, adoption trends, regulatory clearances, reimbursement dynamics, and competitive developments influencing industry growth. It evaluates how AI is reshaping colorectal cancer screening, Barrett's esophagus surveillance, inflammatory bowel disease assessment, and emerging urological and pulmonary applications. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business and investment decisions.

Market Dynamics

The rapid maturation of clinical evidence for AI-assisted colonoscopy remains one of the primary drivers of the AI in endoscopy market, as large multicenter randomized controlled trials have demonstrated statistically significant improvements in adenoma detection rates, a metric directly linked to reduced long-term colorectal cancer risk. The translation of this evidence into formal clinical guidance from leading gastroenterology societies is accelerating procurement decisions, reimbursement consideration, and institutional adoption, transforming AI-assisted colonoscopy from a novel technology into an evidence-backed standard of care.

Expansion across adjacent clinical applications is reshaping the competitive landscape, as the scalability of deep learning-based computer vision models across anatomical regions and imaging modalities is enabling platform providers to extend AI capabilities from colonoscopy into upper GI surveillance, inflammatory bowel disease scoring, capsule endoscopy, and emerging urological and pulmonary applications such as cystoscopy for bladder cancer detection and bronchoscopy for pulmonary nodule navigation. Established endoscopy hardware manufacturers are simultaneously transforming into integrated AI-led care platform providers, launching cloud-based suites that combine detection, characterization, and workflow automation capabilities across their installed equipment base.

Despite strong momentum, the evidence base for several adjacent applications remains earlier-stage than the mature colonoscopy segment, and integration with legacy endoscopy equipment and electronic medical record systems can require significant implementation support. The market nevertheless presents significant long-term opportunities, particularly as ambulatory surgical centers increasingly adopt AI-assisted endoscopy for quality differentiation, and as natural language processing-based automated reporting matures to complement lesion-detection AI investments already made by healthcare institutions.

Segment Analysis

The report provides detailed market analysis across AI technology, component, application, indication, deployment model, end user, and geography, enabling stakeholders to identify high-growth business opportunities and evolving customer requirements.

Based on AI technology, the market is segmented into machine learning and deep learning, natural language processing and automated reporting, predictive analytics and decision support, and other AI technologies. Machine learning and deep learning hold the largest share given their central role in real-time image and video analysis for lesion detection and characterization, while natural language processing and automated reporting are expected to register the fastest growth as institutions seek to automate documentation workflows.

By component, software and AI algorithms represent the largest revenue contributor given the software-centric nature of value creation in this market, while services are the fastest-growing category as healthcare providers increasingly rely on vendors for implementation, integration, and training support. By application, gastrointestinal endoscopy accounts for the largest share given the scale of global colorectal cancer screening programs, while urological endoscopy is the fastest-growing application as the proven AI detection paradigm from colonoscopy extends to surveillance cystoscopy. By indication, colorectal cancer and polyp detection leads, while gastric cancer detection is a significant and growing category particularly in Asia-Pacific markets. By end user, hospitals and endoscopy centers hold the largest share, while ambulatory surgical centers are the fastest-growing category as routine colonoscopy procedures shift toward outpatient settings. By deployment model, on-premise and embedded AI systems currently dominate, while cloud-based AI platforms are the fastest-growing category.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, considering regulatory frameworks, clinical evidence generation, and healthcare infrastructure trends influencing market growth.

North America currently accounts for the largest share of the global AI in endoscopy market, supported by early regulatory clearance of AI-assisted colonoscopy systems, strong clinical research infrastructure generating the randomized trial evidence base that underpins adoption, and a dense commercial ecosystem of established medtech companies and AI health startups. Europe remains a substantial market, benefiting from large-scale randomized controlled trials that have influenced public healthcare procurement and formal AI endorsements from leading gastroenterology societies that are accelerating institutional adoption across EU healthcare systems.

Asia-Pacific is expected to register the fastest growth throughout the forecast period, driven by the region's exceptionally high burden of gastric and colorectal cancers concentrated in Japan, South Korea, and China, rapidly expanding hospital endoscopy infrastructure across India and Southeast Asia, strong government support for AI-based cancer screening programs, and the presence of leading AI endoscopy hardware developers in Japan leveraging high local clinical data volumes to refine detection algorithms.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of key market participants, their product portfolios, clinical evidence generation, regulatory clearances, and recent strategic developments.

Competitive benchmarking enables stakeholders to evaluate companies based on algorithm detection sensitivity and specificity, breadth of clinical validation across indications, integration capability with existing endoscopy infrastructure, and depth of regulatory clearances across major markets. The study also analyzes how established endoscopy hardware manufacturers are transforming into integrated AI-led care platform providers, and how specialized AI software companies are competing to capture share through hardware-agnostic, differentiated detection and characterization solutions.

Key companies profiled in the report include Medtronic plc (Ireland), Olympus Corporation (Japan), FUJIFILM Holdings Corporation (Japan), HOYA Corporation/Pentax Medical (Japan), Intuitive Surgical, Inc. (U.S.), Iterative Health (U.S.), Cosmo Intelligent Medical Devices (Ireland), Odin Vision Ltd. (U.K./Olympus), Karl Storz SE & Co. KG (Germany), Wision AI Co., Ltd. (China), MAGENTIQ EYE Ltd. (Israel), Boston Scientific Corporation (U.S.), Ambu A/S (Denmark), Stryker Corporation (U.S.), and AI Medical Service Inc. (Japan), among others.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the AI in endoscopy market.

Evaluates the impact of clinical trial evidence, regulatory clearances, and guideline endorsements on AI endoscopy adoption.

Identifies high-growth opportunities across AI technologies, components, applications, indications, deployment models, end users, and geographic regions.

Analyzes emerging technology trends, commercialization strategies, and innovation pipelines, including expansion into adjacent GI, urological, and pulmonary applications.

Benchmarks leading companies based on product portfolios, clinical evidence, and competitive positioning.

Supports product development, investment planning, partnership evaluation, market entry, and business expansion strategies.

Delivers actionable market intelligence for endoscopy device manufacturers, AI health technology companies, hospitals, investors, and consultants.

Key Questions Answered

What is the current size of the global AI in endoscopy market, and how is it expected to evolve through 2036?

Which clinical, technological, and regulatory factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which AI technology, component, application, indication, deployment model, end user, and regional segments are expected to experience the strongest growth?

Which geographic markets present the most attractive business opportunities?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent product launches, regulatory clearances, and clinical trial results are shaping the competitive landscape?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?